Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Novo Nordisk A/S made materially false and/or misleading statements and/or failed to disclose that: Novo Nordisk announced on June 23, 2025, that it would end its partnership with Hims & Hers Health, Inc. ("Hims") to distribute its weight loss drug Wegovy, claiming that Hims "has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of ‘personalization' and are disseminating deceptive marketing that put patient safety at risk." Following this news, Novo Nordisk stock fell over 5% on the same day.
In order to be eligible to join the NVO class action lawsuit, you must have incurred a loss on shares of Novo Nordisk A/S purchased during the class period listed above.
TOP
